Reproduction permitted for personal use only. For reprints and reprint permission, contact email@example.com.
It's been one year since the debut of MedTech Futures and it has been a pleasure and a privilege to have the opportunity to share ideas with through this forum. As this column enters its second year, I wanted to take an opportunity to briefly summarize some of the perspectives over the past year and also discuss a topic of great timeliness and importance - namely personalized medicine.Medical technology and pharmaceuticals
The title of this column seems to indicate that medical devices and associated technologies would be the natural topic of discussion. Indeed, over the past year I've written about spine surgery
, the medical design excellence awards
, drug-eluting stents on four occasions (I
), cosmetic implantables
, bioelectromagnetic therapies
, artificial hearts
, and orthopedic technologies
. I've also written several columns on biopharma such as the future of cancer care
, Epogen and pre-dialysis patients
, drug safety
, the BIO2006 conference
, among other articles.
For a medical technology column, that's a fair bit of electronic newsprint being dedicated to pharmaceuticals. One of the most important recurring themes of MedTech Futures has been the convergence of medical technologies. In the article on medical design excellence awards
, for example, I highlighted how devices that incorporate software or electronic connectivity to enhance their safety and usefulness earned high marks in that competition.
In commenting on the GE Healthcare acquisition of Abbott Diagnostics
, I proposed that prognosis is actually more important than diagnosis and that those companies that can provide IT platforms that integrate complex clinical information with their diagnostic tests would be at an advantage. In another article on partnerships in biotech and medtech
, I commented on the importance of combining technologies to achieve innovation advantages.
In the inaugural article
in this MedTech Futures series, I pointed out how technology convergence was a growing theme among orthopedic technologies. In fact, in the reader survey
associated with that column, over 74 percent of you said that medical technology convergence is an exploding sector that's critical today and to the future as compared to about 18.5 percent who said that it was hype that doesn't mean much in today's society. Just over seven percent had never heard of it.
Because over 80 percent of you feel that medical technology convergence is a significant phenomenon or have never heard of it, that's certainly a compelling reason to devote electronic newsprint to the topic. Hopefully over the past year I've answered to some extent that call.Personalized medicine
Personalized medicine. Everyone talks about it. Some call it the future of medicine; some say it is here now. Being, at times, a contrarian, I'm going to tell you it's been around for thousands of years. The practice of surgery (which was done in all of the ancient civilizations from China to Egypt) has always been personalized.
While an abdominal or scalp incision has a fairly generic codification, once that surgeon makes that fateful cut, the operation becomes unique to that patient. Every medical student learns from the first days of anatomy about anomalous hepatic arteries, that an appendix can even be found on the left-hand side of the abdomen and so on. Every patient is unique. Surgery - despite its oft depicted aura of barbarism - is the epitome of personalized medicine.
This fact is very important for the development of modern personalized medicine, which I will touch upon later in this column.The pharmacogenomic interpretation of personalized medicine
Modern personalized medicine has been largely defined in terms of pharmacogenomics, which is the use of a patient's genotype or genetic information to select therapies that are particularly suited to that patient. In fact, Illinois' very own Barack Obama has sponsored a bill now in committee (S. 3822
) entitled the Genomics and Personalized Medicine Act of 2006. You may very well see personalized medicine being featured on presidential campaign ads. This bill provides for some very innovative measures, including:
Creating a Genomics and Personalized Medicine Interagency Working Group within the Department of Health & Human Services.
A number of measures to encourage genomics and biobanking research.
Enhancement of genomics workforce training.
An income tax credit for patients paying for genetic tests or the research related to that test.
The pharmacogenomic part of personalized medicine is indeed a very powerful and promising phenomenon. To some extent it will continue to contribute to the deconstruction of big pharma whose predominant business model based on blockbuster drugs is almost inimical to the personalization of medicine. Many of the safety issues I have written about
have developed because of the basic incompatibility of the blockbuster model with the trend towards personalization (and consequently greater safety) in medicine.
With respect to Vioxx, for example, that drug got into trouble because its use was being extended into areas such as colon cancer prophylaxis, which required long-term use of the drug. More applications, more patients, and longer-term use are the very definition of blockbuster. As I wrote
in my article on Vioxx, the interesting fact is that Merck is contesting (and mostly winning) each claim. That's because, technically speaking, the data only shows the adverse effects with long-term chronic use of the drug.
Generally speaking, that can only be documented for the colon cancer prevention trials and not for the previously established indications. The Epogen controversy is another example I wrote
about which highlights how an indication extension gave another drug (in this case erythropoietin for pre-dialysis renal patients) safety issues.Death of the blockbuster?
It would seem, then, that one of the predictions of personalized medicine is the death of the blockbuster model. Ironically, in an era of personalized medicine, one would think that drug companies would successively decrease the range of indications and patient populations for their drugs. The blockbuster model, however, demands the opposite. The two trends are incompatible and, quite frankly, the whole drug industry model of the future is going to be determined by how this drama plays out.
So what is to be done? This is where technology convergence comes into play. You can read it for yourself but Sen. Obama's (S. 3822) bill actually mandates technology convergence between pharmaceuticals and diagnostics. Basically, among the bill's many provisions, it is stated that the FDA may:
require the sponsor of a drug or biological product (e.g. a drug company) to (1) codevelop a companion diagnostic test, after filing an investigational new drug application or a new drug application to address significant safety concerns of the drug or biological product [and] (2) to develop a companion diagnostic test if phase IV data demonstrate significant safety or effectiveness concerns with use of the drug or biological product
Whether or not this bill passes, technology convergence between pharmaceuticals and diagnostics (also termed theranostics
) is here to stay. How drug companies will embrace that trend will unfold over the coming year or two.Medical technology and personalized medicine
I had indicated earlier that surgery represented the original paradigm of personalized medicine and I don't believe many would dispute that. In this regard, I consider modern personalized medicine as being more than just pharmacogenomics. Advances in electronics miniaturization, materials science, and minimally invasive techniques have made implanted devices more and more of a reality for millions of patients.
The bionic human is also a trend - well documented by a book by Dr. Frank Johnson Health Promotion for People with Implanted Prosthetic Devices
- that is here to stay. Implanted devices, especially if they incorporate various intelligent algorithms, are also a powerful way to implement personalized medicine.
One of the award-worthy devices at the Medical Design Excellence Awards
(MDEA) was the Proprio Foot
motor-powered prosthesis, by Ossur based in Reykjavik, Iceland. A microprocessor driven software program supplements the mechanics of the device that more efficiently mimic different walking styles for the patient. From diabetic amputees to injured Iraq veterans, this represents a significant advance.
Other examples of devices that deliver personalized medicine include various drug-delivery systems that optimize drug dosages, according to patient-specific parameters. This has been, for example, the holy grail of next-generation insulin infusion pumps, which continuously monitor blood glucose levels and deliver exactly the dose of insulin required.
Again, the personalized medicine of this sort implies technology convergence. Convergence between devices and drugs and/or devices and computer software/hardware. Just as with the major pharmaceutical companies, the device companies will also need to meet (perhaps less traumatically) the challenges of technology convergence.
The automobile industry did this when electronics (e.g. telematics) became a larger part of automotive technology. Some companies did this well; others, such as even highly vaunted Mercedes-Benz, encountered significant problems
incorporating electronics into traditional automotive technology.
Technology convergence, appealing as it sounds, is not easy.
So, if I were to encapsulate an entire's year's columns, I would say it would be this:
Technology convergence is an important trend with both challenges and trends for the biopharma and med-tech industries. Technology convergence runs hand-in-hand with personalized medicine - a huge shift in the way medicine will be practiced which will transform clinicians, patients, and business.
Technology convergence was the topic of the very first column
in this series, and I would encourage you to take a look at the reader survey on that page. An overwhelming majority of reader's felt that this was an important trend. This is only the beginning.Previous articles by Ogan Gurel
Of private equity, research, and drug development
Ogan Gurel: What patients want: A story of choice, clinical trials & evidence-based medicine
Ogan Gurel: Healthcare of business: Universal coverage plan includes new business taxes
Ogan Gurel: And the winners in medical design are
Ogan Gurel: A prognosis for GE and Abbott Diagnostics
Dr. Ogan Gurel: Lance Armstrong and the future of cancer care
Dr. Ogan Gurel is chairman of the Aesis Research Group, which provides forward-looking information and research services to the healthcare and life sciences investment community. Gurel was previously CEO of Duravest, a publicly traded Chicago investment company that initiates and develops next-generation medical technologies. Previous to Duravest, he was a vice president and medical director at Sg2, a healthcare intelligence think tank and consultancy serving hospitals and health systems. He can be e-mailed at firstname.lastname@example.org
This article previously appeared in MidwestBusiness.com
, and was reprinted with its permission.
The opinions expressed herein or statements made in the above column are solely those of the author, and do not necessarily reflect the views of Wisconsin Technology Network, LLC.
WTN accepts no legal liability or responsibility for any claims made or opinions expressed herein.